Sinovac Filed Its Annual Report on Form 20-F for 2009

BEIJING, April 16 /PRNewswire-Asia/ — Sinovac Biotech Ltd. (Nasdaq: SVA),
a leading China-based vaccine manufacturer, announced today it filed its
annual report on Form 20-F for the fiscal year ended December 31, 2009 with
the Securities and Exchange Commission on April 16, 2010. The annual report on
Form 20-F can be accessed on Sinovac’s website at
http://www.sinovac.com/Investors/SECFilings/ . Sinovac will provide a hard
copy of the annual report containing its audited consolidated financial
statements, free of charge, to its shareholders upon request.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that
focuses on the research, development, manufacture and commercialization of
vaccines that protect against human infectious diseases. Sinovac’s
commercialized vaccine products include Healive(R) (hepatitis A), Bilive(R)
(combined hepatitis A and B), Anflu(R) (seasonal influenza), Panflu(TM)
(pandemic influenza (H5N1)), and Panflu.1(TM) (pandemic influenza A (H1N1)).
Sinovac is developing vaccines for enterovirus 71, universal pandemic
influenza, pneumococcal infection, Japanese encephalitis, and human rabies.
Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for
independently developed inactivated animal rabies vaccines.

    For further information, please contact:

    Sinovac Biotech Ltd.
     Helen G. Yang
     Tel:  +86-10-8289-0088 x9871
     Fax:  +86-10-6296-6910
     Email: info@sinovac.com

    Investors:
     Amy Glynn/Stephanie Carrington
     The Ruth Group
     Tel:   +1-646-536-7023/7017
     Email: aglynn@theruthgroup.com
            scarrington@theruthgroup.com

    Media
     Janine McCargo
     The Ruth Group
     Tel:    +1-656-536-7033
     Email:  jmccargo@theruthgroup.com

SOURCE Sinovac Biotech Ltd.